ReviewFrontiers in pharmacology2017
NF-κβ: A Potential Target in the Management of Vascular Complications of Diabetes.
Review in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
182 citing papers in PubMed, 4 syntheses or guidelines pooled it, 340 citations in OpenAlex.
- Circulating Galectin-3 levels and Diabetic Nephropathy: a systematic review and meta-analysis.BMC nephrology · 2023Pooled it
- Effects of concurrent aerobic and resistance training on vascular health in type 2 diabetes: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Pooled it
- The Effects of Salvianolate Combined With Western Medicine on Diabetic Nephropathy: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2020Pooled it
- Curcuma longa improves endothelial glycocalyx integrity and redox-inflammatory pathways in type 2 diabetes mellitus: a randomized double-blind placebo-controlled study.European journal of nutrition · 2026Trial
- Examining the oleoylethanolamide supplement effects on glycemic status, oxidative stress, inflammation, and anti-mullerian hormone in polycystic ovary syndrome.Journal of ovarian research · 2024Trial
- Design, Synthesis and Antihyperglycemic/Antilipidemic Activities of Quinoline-thiazolidine-2,4-dione Hybrid.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Combined Omeprazole andInternational journal of molecular sciences · 2026Article
- Investigating the Antidiabetic Effects ofFood science & nutrition · 2026Article
- Reduced Aqueous Humor TGF-β2 Levels in Diabetic Cataract: A Comparative Analysis with NF-κB.Journal of clinical medicine · 2026Article
- Targeting Inflammation in Type 2 Diabetes: The Role of Colchicine.Current diabetes reviews · 2026Review
- Multi-target healing mechanisms ofAvicenna journal of phytomedicine · 2026Article
- The Association of Diabetes and Atherosclerosis: Understanding the Molecular Mechanism of the Double Burden.Current medicinal chemistry · 2026Review
- Impaired Glucose Metabolism in Young Patients with First-episode Schizophrenia Aged from 16 to 35 Years.Current neuropharmacology · 2026Article
- The therapeutic potential of mesenchymal stem cells-derived extracellular vesicles/exosomes on the diabetes: a systematic review study.Diabetology & metabolic syndrome · 2025Review
- Advances in nanomedicine-based retinal drug delivery: mechanisms and translational applications.Journal of nanobiotechnology · 2025Review
- Emerging liposomal therapies for diabetic retinopathy: a review of novel targeting approaches and advances in retinal health outcomes.Drug delivery · 2025Review
- The effects of DPP4 inhibitors, SGLT2 inhibitors and GLP1-RA on the AGE/RAGE pathway: implications for diabetes and its complications.Glycoconjugate journal · 2025Review
- Topical application of phycocyanin accelerates wound healing in STZ-induced diabetic rats via activation of the Nrf2 signaling pathway.3 Biotech · 2025Article
- Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes.International journal of molecular sciences · 2025Review
122 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a metabolic disorder affecting large percentage of population worldwide. NF-κβ plays key role in pathogenesis of vascular complications of diabetes. Persistent hyperglycemia activates NF-κβ that triggers expression of various cytokines, chemokines and cell adhesion molecules. Over-expression of TNF-α, interleukins, TGF-β, Bcl2 and other pro-inflammatory proteins and pro-apoptotic genes by NF-κβ is key risk factor in vascular dysfunction. NF-κβ over-expression also triggers calcification of endothelial cells leading to endothelial dysfunction and further vascular complications. Inhibition of NF-κβ pro-inflammatory pathway is upcoming novel target for management of vascular complications of diabetes. Various natural and synthetic inhibitors of NF-κβ have been studied in management of diabetic complications. Recent preclinical and clinical studies validate NF-κβ as promising target in the management of vascular complications of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.